
The COMPOSE study is evaluating pegtibatinase, an investigational drug that has not been approved by the FDA, in children ages 5 to 11 with classical homocystinuria (HCU). In HCU, a substance called homocysteine builds up in the blood. Pegtibatinase is designed to help prevent this buildup. Researchers want to learn how safe the study drug is in children, how well they tolerate it, and whether it affects homocysteine-related levels in the blood. This is the first time pegtibatinase is being given to children in this age group.
Every child receives the study drug; there is no placebo. Doses start low and may increase over 20 weeks, and the study doctor checks how your child is doing before each increase. Medicines often need to be studied specifically in children to understand safe and appropriate doses, and what researchers learn here will help determine whether pegtibatinase could be used to treat HCU in the future. Your child may or may not benefit directly.
This study is a real commitment: up to 42 weeks, with visits about twice a week during dosing. Science 37 makes that more manageable by bringing the study to you. For most visits, a nurse or healthcare professional comes to your home, and the study drug is delivered to your door. Clinic travel is needed only for an eye exam and a bone scan, if one is required.
Like all research, this study has possible risks, including injection-site and allergic reactions, which the study team will review with you in detail. Participation is voluntary, and you can withdraw your child at any time without affecting their regular care.









